<SEC-DOCUMENT>0001062822-21-000060.txt : 20211103
<SEC-HEADER>0001062822-21-000060.hdr.sgml : 20211103
<ACCEPTANCE-DATETIME>20211103160529
ACCESSION NUMBER:		0001062822-21-000060
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20211103
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211103
DATE AS OF CHANGE:		20211103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		211375307

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrx-20211103.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:80e01159-b9e1-434d-b451-5bfcf42cc1d5,g:eef9fe8d-7a1b-40b2-8e7f-bf535f251bfd,d:57caecadfb78464b855c8928d1ea6498--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20211103</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF80L2ZyYWc6Njc4NTkxZTY2OGRkNGYxNjg4NmFiY2E4ZTAyZDI4NGIvdGFibGU6OWIwZTk1NWI2ZDY5NGNlN2E5YWM1OGNhYjI4MjNiNDYvdGFibGVyYW5nZTo5YjBlOTU1YjZkNjk0Y2U3YTlhYzU4Y2FiMjgyM2I0Nl8wLTEtMS0xLTE1NjQw_caa69e51-8e29-4ae3-b7e0-c9e7668b2d60">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF80L2ZyYWc6Njc4NTkxZTY2OGRkNGYxNjg4NmFiY2E4ZTAyZDI4NGIvdGFibGU6OWIwZTk1NWI2ZDY5NGNlN2E5YWM1OGNhYjI4MjNiNDYvdGFibGVyYW5nZTo5YjBlOTU1YjZkNjk0Y2U3YTlhYzU4Y2FiMjgyM2I0Nl8xLTEtMS0xLTE1NjQw_63ef0841-256d-45ad-96de-859d52dd2eac">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20211103.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i57caecadfb78464b855c8928d1ea6498_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzc3_f4cd15b7-5103-4426-b885-985504a4e6a8">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8yNjU_053a8191-1912-4669-8a3d-9ede1ce17d7c">November 3, 2021</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzgy_29fadf05-1514-413f-9ace-86dbf773820f">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:32.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6NTY2ODcyYjU3M2YxNGNkZmJjZGVhOGNlYTJjZDVhNWUvdGFibGVyYW5nZTo1NjY4NzJiNTczZjE0Y2RmYmNkZWE4Y2VhMmNkNWE1ZV8wLTAtMS0xLTE1NjQw_4f9e16ab-430f-4c2a-beda-a0d711381e2e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6NTY2ODcyYjU3M2YxNGNkZmJjZGVhOGNlYTJjZDVhNWUvdGFibGVyYW5nZTo1NjY4NzJiNTczZjE0Y2RmYmNkZWE4Y2VhMmNkNWE1ZV8wLTEtMS0xLTE1NjQw_824b8e03-4369-41c3-b48a-f21e6f231ef6">000-30111</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6NTY2ODcyYjU3M2YxNGNkZmJjZGVhOGNlYTJjZDVhNWUvdGFibGVyYW5nZTo1NjY4NzJiNTczZjE0Y2RmYmNkZWE4Y2VhMmNkNWE1ZV8wLTItMS0xLTE1NjQw_a3aeb93b-2d68-484d-9de9-ea67930c7fc6">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzg2_a5dbc90e-fd56-4925-a2f7-f90c2100c73d">2445 Technology Forest Blvd., 11th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzgz_f2a51fd7-3fd3-4770-87e3-e002906e1781">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzc4_568faa44-85a4-41c6-8374-52a1b24a2b7f">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF80MjA_c6b2c146-c4d7-477a-b261-94e49b997358">77381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices and Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF80Nzk_8f6f69d8-b3fe-42ff-8f1c-0c40fcc5e194">281</ix:nonNumeric>) <ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzc0_9cc939d9-3706-4389-b9db-89e03185b6a6">863-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8800 Technology Forest Place</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF81NzU_f2a51fd7-3fd3-4770-87e3-e002906e1781">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF81Nzk_568faa44-85a4-41c6-8374-52a1b24a2b7f">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF81ODI_c6b2c146-c4d7-477a-b261-94e49b997358">77381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former address if changed since last report)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:34.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6YjQyYTgxNmY2MmU4NGMzYWJlYzhmMjkxODgzM2U3ZTUvdGFibGVyYW5nZTpiNDJhODE2ZjYyZTg0YzNhYmVjOGYyOTE4ODMzZTdlNV8xLTAtMS0xLTE1NjQw_a2ba67b5-131d-48be-8c27-24aa5a9959c4">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6YjQyYTgxNmY2MmU4NGMzYWJlYzhmMjkxODgzM2U3ZTUvdGFibGVyYW5nZTpiNDJhODE2ZjYyZTg0YzNhYmVjOGYyOTE4ODMzZTdlNV8xLTEtMS0xLTE1NjQw_ca9bc109-44c1-4b1a-a732-d1536e15b15d">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6YjQyYTgxNmY2MmU4NGMzYWJlYzhmMjkxODgzM2U3ZTUvdGFibGVyYW5nZTpiNDJhODE2ZjYyZTg0YzNhYmVjOGYyOTE4ODMzZTdlNV8xLTItMS0xLTE1NjQw_cb47e0df-6d53-4e13-a9be-83b435d58a43">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzg3_619de936-9f4f-4c07-bef0-6629bb98221f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17&#160;CFR&#160;230.425)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzc1_5b969f4d-3913-463f-ac13-d4ec8e460374">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17&#160;CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzg1_037c4d4c-5b65-4c55-8553-8655e1422d22">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR 240.14d-2(b))</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzgw_8fe96272-2262-41f4-bfda-7e99c3102ddb">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzgx_9e66c408-7142-414c-b234-f11e34e3a71c">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i57caecadfb78464b855c8928d1ea6498_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operation and Financial Condition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 3, 2021, we issu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ed a press release to report our financial results for the quarter ended September 30, 2021.  A copy of the press release is attached to this current report on Form&#160;8-K as Exhibit&#160;99.1.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i57caecadfb78464b855c8928d1ea6498_10"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:13.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings2021-1.htm">Press Release of Lexicon Pharmaceuticals, Inc. dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings2021-1.htm">November</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings2021-1.htm"> 3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings2021-1.htm">, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EX-104</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i57caecadfb78464b855c8928d1ea6498_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:50.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:   November 3, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and General Counsel</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseearnings2021-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i35412df3e71c44119e4e06560fadd7f1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Conference Call and Webcast at 5&#58;00 pm Eastern Time</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">The Woodlands, Texas, November 3, 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> - </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon Pharmaceuticals, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (Nasdaq&#58; LXRX), today reported financial results for the three months ended September 30, 2021 and provided an update on key milestones.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We are on track for submission around year-end of our new drug application for sotagliflozin for the treatment of heart failure in patients with type 2 diabetes,&#8221; said Lonnel Coats, Lexicon&#8217;s chief executive officer. &#8220;Momentum continues to build for the adoption of SGLT inhibitors into the first-line heart failure treatment regimen, as most recently evidenced by the new clinical practice guidelines issued in late August by the European Society of Cardiology (ESC). We believe that sotagliflozin&#8217;s unique mechanism of action as a dual SGLT1 and SGLT2 inhibitor offers differentiating advantages in this emerging market, with a particular opportunity in heart failure with preserved ejection fraction (HFpEF), and that a primary point of engagement will be with specialists treating patients who have been recently hospitalized for worsening heart failure, which was the cornerstone of our SOLOIST study.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We are building our launch readiness team in preparation for potentially bringing sotagliflozin to patients suffering from heart failure and living with type 2 diabetes next year.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Third Quarter Highlights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Sotagliflozin</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#242424;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.5pt">ESC issued new treatment guidelines adding SGLT inhibitors to the standard of care for the prevention and treatment of heart failure.</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Sotagliflozin was specifically recommended for the primary prevention of heart failure in type 2 diabetes patients with risk factors for its development and the treatment of heart failure in patients with type 2 diabetes, and was also noted in the guidelines in the context of worsening heart failure.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.5pt">Additional analyses of sotagliflozin data from the SOLOIST and SCORED Phase 3 clinical studies were presented at the ESC Congress 2021 highlighting the benefits seen in reduced heart failure hospitalizations, myocardial infarction and stroke. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">LX9211</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.5pt">Patient enrollment continued in two ongoing Phase 2 clinical studies of LX9211 for the treatment of diabetic peripheral neuropathic pain and the treatment of post-herpetic neuralgia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Results from these clinical studies are currently expected in the first half of 2022.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Corporate</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.5pt">Craig B. Granowitz, M.D., Ph.D. joined Lexicon as senior vice president and chief medical officer, with a deep and successful history in cardiovascular medicine.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Dr. Granowitz will lead the build-out of Lexicon&#8217;s medical affairs organization as the company prepares for the potential launch of sotagliflozin for the treatment of heart failure in patients with type 2 diabetes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Third Quarter 2021 Financial Highlights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Revenues&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Revenues for the three months ended September 30, 2021 were negligible as compared to $6.6 million for the corresponding period in 2020, primarily due to the absence of product revenues as a result of Lexicon&#8217;s sale of its XERMELO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> product and related assets to TerSera Therapeutics LLC during the third quarter of 2020. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Research and Development (R&#38;D) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Research and development expenses for the three months ended September 30, 2021 decreased to $15.7 million from $40.1 million for the corresponding period in 2020, primarily due to decreases in external clinical development costs related to sotagliflozin resulting from the completion of clinical studies.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Selling, General and Administrative (SG&#38;A) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Selling, general and administrative expenses for the three months ended September 30, 2021 decreased to $7.3 million from $12.0 million for the corresponding period in 2020, primarily due to lower salaries and benefits costs as a result of reductions in personnel in September 2020 and lower marketing expenses, all primarily associated with the sale of XERMELO and related assets during the third quarter of 2020. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Net Loss&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Net loss for the three months ended September 30, 2021 was $23.1 million, or $0.16 per share, as compared to net income of $82.6 million, or $0.71 per diluted share, in the corresponding period in 2020.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The three months ended September 30, 2020 included a gain of $132.8 million from the sale of XERMELO and related assets to TerSera. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For the three months ended September 30, 2021 and 2020, net income included non-cash, stock-based compensation expense of $2.7 million and $1.9 million, respectively.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Cash and Investments&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> As of September 30, 2021, Lexicon had $120.9 million in cash and investments, as compared to $152.3 million as of December 31, 2020.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Conference Call and Webcast Information</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon management will hold a live conference call and webcast today at 5&#58;00 pm ET &#47; 4&#58;00 pm CT to review its financial and operating results and to provide a general business update. The dial-in number for the conference call is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">888-645-5785</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (U.S.&#47;Canada) or 970-300-1531 (international). The conference ID for all callers is 8564549. The live webcast and replay may be accessed by visiting Lexicon&#8217;s website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.lexpharma.com&#47;events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. An archived version of the webcast will be available on the website for 14 days. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About the SOLOIST and SCORED Studies</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SOLOIST was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584 patients with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> of body-surface area, and risks for cardiovascular disease. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Both SOLOIST and SCORED achieved their respective primary endpoints.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Results from both studies were presented at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">The New England Journal of Medicine (NEJM)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> in two separate articles titled&#58; &#8220;Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure&#8221; and &#8220;Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Lexicon Pharmaceuticals</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives. Through its Genome5000&#8482; program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For additional information, please visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.lexpharma.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Safe Harbor Statement</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">This press release contains &#8220;forward-looking statements,&#8221; including statements relating to Lexicon&#8217;s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin, LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon&#8217;s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management&#8217;s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon&#8217;s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#8217;s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under &#8220;Risk Factors&#8221; in Lexicon&#8217;s annual report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i35412df3e71c44119e4e06560fadd7f1_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Selected Financial Data</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations Data</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ -</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ 6,542</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ -</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,404</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative agreements</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,634</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,796</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (including finite-lived intangible</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;asset amortization)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1929</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $1,138, $1,029, $3,608 and $5,154, respectively</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,682</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,147</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,548</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,629</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $1,574, $875, $4,741, and $5,440, respectively</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,303</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,997</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,496</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,798</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on buildings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,985</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,777</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,044</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,956</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of XERMELO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,818</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,818</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,962)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,675</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,760)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,342)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on debt extinguishments, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,118)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(507)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,374)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (23,122)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ 82,603</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (62,147)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (53,079)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share, basic</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (0.16)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ 0.77</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (0.43)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (0.50)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share, diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (0.16)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ 0.71</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (0.43)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (0.50)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;common share, basic&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,820</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,309</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,558</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;common share, diluted&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;  </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,820</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,552</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,558</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sept. 30, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash and investments&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ 120,918</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ 152,275</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Property and equipment, net&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Goodwill&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;....</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,543</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,543</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total assets&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,330</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,788</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current debt&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;  </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,693</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,646</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Accumulated deficit&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;  </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,462,165)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400,018)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total stockholders' equity&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,603</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,371</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i35412df3e71c44119e4e06560fadd7f1_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">For Inquiries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Chas Schultz</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Executive Director, Corporate Communications and Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Lexicon Pharmaceuticals</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">(281) 863-3421</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">cschultz&#64;lexpharma.com</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lxrx-20211103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:80e01159-b9e1-434d-b451-5bfcf42cc1d5,g:eef9fe8d-7a1b-40b2-8e7f-bf535f251bfd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20211103" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20211103">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20211103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20211103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.lexpharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lxrx-20211103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:80e01159-b9e1-434d-b451-5bfcf42cc1d5,g:eef9fe8d-7a1b-40b2-8e7f-bf535f251bfd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_a6f206a2-9540-49e2-97d1-84a973515ceb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_97b24ca8-17ed-4e97-a5a8-c4628c13017f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d593a311-519d-4b0b-b0e9-50de9f4f5985_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_757953af-e7d0-4bc9-88e9-f5c968edca4e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a616ceb8-7c94-42de-8cb6-35d1a6d1a313_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2435d60b-6bbc-4288-8f41-62fd0d695f4d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_32c115be-0a76-4c3d-b3d2-2682737bfe58_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_caf14b50-3f7c-40b7-9090-893a7ddcec56_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9c261ddd-65e4-4118-97ba-aac757da6d63_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_4cdf6a7b-7e22-400d-b0ea-5043d0add653_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3c39642f-e5b5-49e6-85da-6153735c4c3b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_912d05a4-dc6e-4b04-a7fe-caa28025ce66_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_66c070ea-1138-4743-bf7e-4c27729f6c41_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_029b339d-065d-4eb5-be0d-3127fce7bbad_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ecaf6d5f-a703-499f-b05c-6ee762e8ad3f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1d14d7cf-a5f4-45a7-8f62-60043399922d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3fb52251-6272-429b-aede-3f6c92d33c98_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a1ba8ebb-2c0e-47cb-b605-80913dd44140_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f9a1e3bb-e216-46cf-bb01-2728eda6ecd7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ce0826cc-7d0f-437a-afb3-6c0343c39bbd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_918620f1-95d3-4cff-b01d-22f7aad88e4a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a55bf79a-4ce4-453a-84c6-fe3f876fd2de_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>lxrx-20211103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:80e01159-b9e1-434d-b451-5bfcf42cc1d5,g:eef9fe8d-7a1b-40b2-8e7f-bf535f251bfd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20211103.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e42fabdd-bb9c-41d6-8eca-061afd20b080" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_DocumentType_e42fabdd-bb9c-41d6-8eca-061afd20b080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e588abb3-2b91-4259-8f6b-d39152b88b79" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_DocumentPeriodEndDate_e588abb3-2b91-4259-8f6b-d39152b88b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ef6088c6-fb96-4e51-9952-4ffbf9bba241" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_EntityRegistrantName_ef6088c6-fb96-4e51-9952-4ffbf9bba241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c0f41803-7dce-4544-8f10-80a51e764c88" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c0f41803-7dce-4544-8f10-80a51e764c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_721b8bc0-59cb-4269-84ec-9ff64158257e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_EntityFileNumber_721b8bc0-59cb-4269-84ec-9ff64158257e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_aa9f73ce-73e7-4bb1-b7ac-6649d0a9d6a1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_EntityTaxIdentificationNumber_aa9f73ce-73e7-4bb1-b7ac-6649d0a9d6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_58a267c1-8120-4ef1-a192-9f64cdd8ddb6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_EntityAddressAddressLine1_58a267c1-8120-4ef1-a192-9f64cdd8ddb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_db2776a0-d85d-405e-b3e7-0b1a69bbf80d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_EntityAddressCityOrTown_db2776a0-d85d-405e-b3e7-0b1a69bbf80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8c43502d-2e2b-49ef-a246-5847701ab2f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_EntityAddressStateOrProvince_8c43502d-2e2b-49ef-a246-5847701ab2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_76ef4b0b-5a97-41db-93c8-2eed3ef1742a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_EntityAddressPostalZipCode_76ef4b0b-5a97-41db-93c8-2eed3ef1742a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d32fd816-7281-4aa9-a857-51441a97e1d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_CityAreaCode_d32fd816-7281-4aa9-a857-51441a97e1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d69ad0e5-0cb0-4885-b1be-7dc1f6482017" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_LocalPhoneNumber_d69ad0e5-0cb0-4885-b1be-7dc1f6482017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6753f970-be05-4052-9425-e46d0f63c09a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_Security12bTitle_6753f970-be05-4052-9425-e46d0f63c09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d91f1249-6907-4c94-a064-ed94b8b342b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_TradingSymbol_d91f1249-6907-4c94-a064-ed94b8b342b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3677e2d2-a66c-4eb2-b437-a29252ce2e88" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_SecurityExchangeName_3677e2d2-a66c-4eb2-b437-a29252ce2e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_ceeff8e2-d842-4a11-9522-aff02f98df7d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_WrittenCommunications_ceeff8e2-d842-4a11-9522-aff02f98df7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_30d0d332-d35e-44af-9d48-a3d88654b2a3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_SolicitingMaterial_30d0d332-d35e-44af-9d48-a3d88654b2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_aeccddbc-28a1-4182-a1a4-59f1a9e5b063" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_PreCommencementTenderOffer_aeccddbc-28a1-4182-a1a4-59f1a9e5b063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_90fdab1b-94ea-4916-93f1-69156d682a74" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_90fdab1b-94ea-4916-93f1-69156d682a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_14c13745-e3b7-49be-b5d9-458fa4c0361a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_EntityEmergingGrowthCompany_14c13745-e3b7-49be-b5d9-458fa4c0361a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_78d625b5-1274-490e-b648-a6eba8b5cff7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_EntityCentralIndexKey_78d625b5-1274-490e-b648-a6eba8b5cff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3a10e573-633d-4c6f-aaf2-03ced3a31764" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab5e8c7c-4417-4e56-a91b-10bc6b858ad6" xlink:to="loc_dei_AmendmentFlag_3a10e573-633d-4c6f-aaf2-03ced3a31764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>lxrx-20211103_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20211103.xsd" xlink:type="simple"/>
    <context id="ieff92076e7974bde8828b401e970f16c_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF80L2ZyYWc6Njc4NTkxZTY2OGRkNGYxNjg4NmFiY2E4ZTAyZDI4NGIvdGFibGU6OWIwZTk1NWI2ZDY5NGNlN2E5YWM1OGNhYjI4MjNiNDYvdGFibGVyYW5nZTo5YjBlOTU1YjZkNjk0Y2U3YTlhYzU4Y2FiMjgyM2I0Nl8wLTEtMS0xLTE1NjQw_caa69e51-8e29-4ae3-b7e0-c9e7668b2d60">0001062822</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF80L2ZyYWc6Njc4NTkxZTY2OGRkNGYxNjg4NmFiY2E4ZTAyZDI4NGIvdGFibGU6OWIwZTk1NWI2ZDY5NGNlN2E5YWM1OGNhYjI4MjNiNDYvdGFibGVyYW5nZTo5YjBlOTU1YjZkNjk0Y2U3YTlhYzU4Y2FiMjgyM2I0Nl8xLTEtMS0xLTE1NjQw_63ef0841-256d-45ad-96de-859d52dd2eac">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzc3_f4cd15b7-5103-4426-b885-985504a4e6a8">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8yNjU_053a8191-1912-4669-8a3d-9ede1ce17d7c">2021-11-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzgy_29fadf05-1514-413f-9ace-86dbf773820f">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6NTY2ODcyYjU3M2YxNGNkZmJjZGVhOGNlYTJjZDVhNWUvdGFibGVyYW5nZTo1NjY4NzJiNTczZjE0Y2RmYmNkZWE4Y2VhMmNkNWE1ZV8wLTAtMS0xLTE1NjQw_4f9e16ab-430f-4c2a-beda-a0d711381e2e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6NTY2ODcyYjU3M2YxNGNkZmJjZGVhOGNlYTJjZDVhNWUvdGFibGVyYW5nZTo1NjY4NzJiNTczZjE0Y2RmYmNkZWE4Y2VhMmNkNWE1ZV8wLTEtMS0xLTE1NjQw_824b8e03-4369-41c3-b48a-f21e6f231ef6">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6NTY2ODcyYjU3M2YxNGNkZmJjZGVhOGNlYTJjZDVhNWUvdGFibGVyYW5nZTo1NjY4NzJiNTczZjE0Y2RmYmNkZWE4Y2VhMmNkNWE1ZV8wLTItMS0xLTE1NjQw_a3aeb93b-2d68-484d-9de9-ea67930c7fc6">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzg2_a5dbc90e-fd56-4925-a2f7-f90c2100c73d">2445 Technology Forest Blvd., 11th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzgz_f2a51fd7-3fd3-4770-87e3-e002906e1781">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzc4_568faa44-85a4-41c6-8374-52a1b24a2b7f">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF80MjA_c6b2c146-c4d7-477a-b261-94e49b997358">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF80Nzk_8f6f69d8-b3fe-42ff-8f1c-0c40fcc5e194">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzc0_9cc939d9-3706-4389-b9db-89e03185b6a6">863-3000</dei:LocalPhoneNumber>
    <dei:EntityAddressCityOrTown
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF81NzU_f2a51fd7-3fd3-4770-87e3-e002906e1781">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF81Nzk_568faa44-85a4-41c6-8374-52a1b24a2b7f">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF81ODI_c6b2c146-c4d7-477a-b261-94e49b997358">77381</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6YjQyYTgxNmY2MmU4NGMzYWJlYzhmMjkxODgzM2U3ZTUvdGFibGVyYW5nZTpiNDJhODE2ZjYyZTg0YzNhYmVjOGYyOTE4ODMzZTdlNV8xLTAtMS0xLTE1NjQw_a2ba67b5-131d-48be-8c27-24aa5a9959c4">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6YjQyYTgxNmY2MmU4NGMzYWJlYzhmMjkxODgzM2U3ZTUvdGFibGVyYW5nZTpiNDJhODE2ZjYyZTg0YzNhYmVjOGYyOTE4ODMzZTdlNV8xLTEtMS0xLTE1NjQw_ca9bc109-44c1-4b1a-a732-d1536e15b15d">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGFibGU6YjQyYTgxNmY2MmU4NGMzYWJlYzhmMjkxODgzM2U3ZTUvdGFibGVyYW5nZTpiNDJhODE2ZjYyZTg0YzNhYmVjOGYyOTE4ODMzZTdlNV8xLTItMS0xLTE1NjQw_cb47e0df-6d53-4e13-a9be-83b435d58a43">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzg3_619de936-9f4f-4c07-bef0-6629bb98221f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzc1_5b969f4d-3913-463f-ac13-d4ec8e460374">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzg1_037c4d4c-5b65-4c55-8553-8655e1422d22">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzgw_8fe96272-2262-41f4-bfda-7e99c3102ddb">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="ieff92076e7974bde8828b401e970f16c_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3Y2FlY2FkZmI3ODQ2NGI4NTVjODkyOGQxZWE2NDk4L3NlYzo1N2NhZWNhZGZiNzg0NjRiODU1Yzg5MjhkMWVhNjQ5OF8xL2ZyYWc6NGMzZWQ1NjIyOTg4NDZjZjhjMTQwNWU0N2RiMDE2M2QvdGV4dHJlZ2lvbjo0YzNlZDU2MjI5ODg0NmNmOGMxNDA1ZTQ3ZGIwMTYzZF8xNzgx_9e66c408-7142-414c-b234-f11e34e3a71c">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140103284240568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  03,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd., 11th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M 0  (@(   \   !X;"]W;W)K8F]O:RYX;6R-4=%NPC ,_)4J'[ 6M"$-45Y
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( *N 8U,'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ JX!C4\21Z%3M    *P(  !$
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M;',O+G)E;'-02P$"% ,4    " "K@&-3JL0B%C,!   B @  #P
M    @ %&$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ JX!C4R0>FZ*M
M    ^ $  !H              ( !IA$  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ JX!C4V60>9(9 0  SP,  !,
M ( !BQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  U1,
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lxrx-20211103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lxrx-20211103.htm">lxrx-20211103.htm</File>
    <File>lxrx-20211103.xsd</File>
    <File>lxrx-20211103_lab.xml</File>
    <File>lxrx-20211103_pre.xml</File>
    <File>pressreleaseearnings2021-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20211103.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "lxrx-20211103.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20211103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20211103_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20211103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20211103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211103.htm",
      "contextRef": "ieff92076e7974bde8828b401e970f16c_D20210730-20210730",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.lexpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20211103.htm",
      "contextRef": "ieff92076e7974bde8828b401e970f16c_D20210730-20210730",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001062822-21-000060-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-21-000060-xbrl.zip
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M:ZLT#+?;[7@[&2N]#N,H(N']M]6UAP8=MA#R88!N,EWT^$G8JC-JX ^\T<T
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M]<>;M:O+93 L,BX,48:B MX(8JD2!((13KM,<,='(."!T6'IG_ 8\^423J0
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MVHG":4>]*Y';88$"BJ^98[FG'?Y5B/\L;?<DXK]B<SY;_$_A,YW1!&+1<)#
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M4NXPGX56&!-?VK73J;H^"Q2'YXFZ81HH8"S2-C/S?3#2G2P$$YV LZAR0<K
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M-TS0&_=3(BVCI^_9K!3&0@UJGQO0-RS4'3_*\]AG-*6SP)VPG7EKBS$43&'
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M4$L! A0#%     @ K(!C4[Q$_O1 %   L(8  !$              ( !
M &QX<G@M,C R,3$Q,#,N:'1M4$L! A0#%     @ K(!C4SVDTG)O @  ?0<
M !$              ( !;Q0  &QX<G@M,C R,3$Q,#,N>'-D4$L! A0#%
M  @ K(!C4ZN@P(U "@  HET  !4              ( !#1<  &QX<G@M,C R
M,3$Q,#-?;&%B+GAM;%!+ 0(4 Q0    ( *R 8U/S_7:TK08  &@Q   5
M          "  8 A  !L>')X+3(P,C$Q,3 S7W!R92YX;6Q02P$"% ,4
M" "L@&-3@I6^I3X;  !I&@$ '@              @ %@*   <')E<W-R96QE
K87-E96%R;FEN9W,R,#(Q+3$N:'1M4$L%!@     %  4 4 $  -I#      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
